Bundesverband der Pharmazeutischen Industrie

Statistics Show Opportunity to Gain More Commercial Drivers in 2022

Retrieved on: 
Wednesday, March 2, 2022
Second Chance Program, NRC, Perception, Morale, Employment, Bundesverband der Pharmazeutischen Industrie, Policy, Industry, SAP, Substance abuse, Motivation, Safety, SAE, Program, ASAP, Statistics, Sexual abuse, Nuclear Regulatory Commission, DOT, Department of transportation, CM, DER, Department, Case management, Health insurance

BALTIMORE, Md., March 2, 2022 /PRNewswire-PRWeb/ --The lack of drivers has delivered a blow to the nation's supply chain and economy.

Key Points: 
  • BALTIMORE, Md., March 2, 2022 /PRNewswire-PRWeb/ --The lack of drivers has delivered a blow to the nation's supply chain and economy.
  • However, there are thousands of drivers ready to go back to work if given a second chance.
  • Companies with DOT employees are required to have a DOT drug and alcohol testing policy that maintains the guidance for a drug free workplace.
  • In 2021, according to ASAP statistics, an increase of 22% of DERs were involved in helping DOT employees get a second chance at their employment.

Ethris Receives “Most Innovative Product Top 3” Award for COVID-19 Therapeutic Candidate at 22nd Pharma Trend Image & Innovation Award

Retrieved on: 
Wednesday, September 15, 2021
Health, Infectious Diseases, Genetics, Research, Science, Pharmaceutical, Biotechnology, Gesellschaft mit beschränkter Haftung, Innovation, Respiratory system, Science, Deutsches Museum, Biotechnology, CEO, Coronavirus, People's State of Bavaria, Gene, III, Association, Innovative Products of America, Severe acute respiratory syndrome coronavirus 2, Therapy, Bundesverband der Pharmazeutischen Industrie, Rx, COVID-19, RNA, RNA transfection, OTC, Research, Lung, Pharmaceutical industry, Vaccine

Ethris GmbH announced today that its lead COVID-19 therapeutic candidate, ETH47, has been awarded "Most Innovative Product Top 3" in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.

Key Points: 
  • Ethris GmbH announced today that its lead COVID-19 therapeutic candidate, ETH47, has been awarded "Most Innovative Product Top 3" in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.
  • ETH47 is a therapeutic candidate that harbors the mRNA blueprint for type III interferon.
  • The prize was presented to Dr. Carsten Rudolph, CEO of Ethris, at a ceremony on September 14, 2021 at the Deutches (German) Museum in Munich, Germany.
  • Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies.

United States' Corporate Pharma Reputation in 2019 - Survey Findings from 186 Patient Groups

Retrieved on: 
Tuesday, August 4, 2020
Health, Pharmaceutical sciences, Pharmaceutical industry, Pharmacology, Pharmacy, Draft:Piramal Pharma Solutions, Bundesverband der Pharmazeutischen Industrie

Company analyses: 39 pharma companies analysed for performance at 12 indicators of corporate reputation by US patient groups familiar with the company, and by US patient groups that work or partner with the company.

Key Points: 
  • Company analyses: 39 pharma companies analysed for performance at 12 indicators of corporate reputation by US patient groups familiar with the company, and by US patient groups that work or partner with the company.
  • 48% of 2019's respondent US patient groups stated that the pharmaceutical industry had an Excellent or Good corporate reputation.
  • However, US patient groups only ranked the pharmaceutical industry 3rd in 2019 for corporate reputation out of nine healthcare sectors; the pharmaceutical industry was ranked 1st by patient groups worldwide.
  • US patient-group relationships with pharma, 2019
    Rankings of the 39 pharma companies, 2019 (v. 2018) among US patient groups familiar with the companies
    Rankings of the 23 pharma companies, 2019 (v. 2018) among US patient groups that work with the companies
    Profiles of the 39 companies, 2019 (v. 2018)